At Edwards, we intend to shape future treatments. An approximately 20 percent increase in research and development spending in 2002 attests to Edwards’ commitment to the scientific exploration of new technologies to fulfill unmet clinical needs in cardiovascular disease.  A major component of our strategy involves extending our leading heart valve therapy and  critical care franchises. 